IL-6 signal transduction and its physiological roles: the signal orchestration model
Top Cited Papers
- 29 October 2003
- book chapter
- Published by Springer Nature
- Vol. 149, 1-38
- https://doi.org/10.1007/s10254-003-0012-2
Abstract
Interleukin (IL)-6 is a pleiotropic cytokine that not only affects the immune system, but also acts in other biological systems and many physiological events in various organs. In a target cell, IL-6 can simultaneously generate functionally distinct or sometimes contradictory signals through its receptor complex, IL-6Rα and gp130. One good illustration is derived from the in vitro observations that IL-6 promotes the growth arrest and differentiation of M1 cells through gp130-mediated STAT3 activation, whereas the Y759/SHP-2-mediated cascade by gp130 stimulation has growth-enhancing effects. The final physiological output can be thought of as a consequence of the orchestration of the diverse signaling pathways generated by a given ligand. This concept, the signal orchestration model, may explain how IL-6 can elicit proinflammatory or anti-inflammatory effects, depending on the in vivo environmental circumstances. Elucidation of the molecular mechanisms underlying this issue is a challenging subject for future research. Intriguingly, recent in vivo studies indicated that the SHP-2-binding site- and YXXQ-mediated pathways through gp130 are not mutually exclusive but affect each other: a mutation at the SHP-2-binding site prolongs STAT3 activation, and a loss of STAT activation by gp130 truncation leads to sustained SHP-2/ERK MAPK phosphorylation. Although IL-6/gp130 signaling is a promising target for drug discovery for many human diseases, the interdependence of each signaling pathway may be an obstacle to the development of a nonpeptide orally active small molecule to inhibit one of these IL-6 signaling cascades, because it would disturb the signal orchestration. In mice, a consequence of the imbalanced signals causes unexpected results such as gastrointestinal disorders, autoimmune diseases, and/or chronic inflammatory proliferative diseases. However, lessons learned from IL-6 KO mice indicate that IL-6 is not essential for vital biological processes, but a significant impact on disease progression in many experimental models for human disorders. Thus, IL-6/gp130 signaling will become a more attractive therapeutic target for human inflammatory diseases when a better understanding of IL-6 signaling, including the identification of the conductor for gp130 signal transduction, is achieved.Keywords
This publication has 213 references indexed in Scilit:
- A Point Mutation of Tyr-759 in Interleukin 6 Family Cytokine Receptor Subunit gp130 Causes Autoimmune ArthritisThe Journal of Experimental Medicine, 2002
- Intracerebroventricular interleukin-6 treatment decreases body fat in ratsBiochemical and Biophysical Research Communications, 2002
- Tissue-Specific Autoregulation of the stat3 Gene and Its Role in Interleukin-6-Induced Survival Signals in T CellsMolecular and Cellular Biology, 2001
- Molecular Basis Underlying Functional Pleiotropy of Cytokines and Growth FactorsBiochemical and Biophysical Research Communications, 1999
- IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses.Journal of Clinical Investigation, 1998
- Serum Interleukin-6 Is Related to Disease Activity but Not Disease Specificity in Inflammatory Bowel DiseaseJournal of Clinical Gastroenterology, 1995
- The acute phase responseImmunology Today, 1994
- SH2 domains recognize specific phosphopeptide sequencesPublished by Elsevier ,1993
- Phosphorylation of secreted forms of human β2-interferon/hepatocyte stimulating factor/interleukin-6Biochemical and Biophysical Research Communications, 1988
- Isolation of hepatocyte stimulating factor from human monocytesBiochemical and Biophysical Research Communications, 1987